Breast Cancer in Pregnancy Register Study

Rekrutierend

NCT-Nummer:
NCT00196833

Studienbeginn:
April 2003

Letztes Update:
17.04.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Breast Neoplasms

Geschlecht:
Frauen

Altersgruppe:
Alle

Phase:
-

Sponsor:
German Breast Group

Collaborator:
Goethe University

Studienleiter

Sibylle Loibl, Prof. Dr.
Principal Investigator
German Breast Group

Kontakt

Sibylle Loibl, Prof. Dr.
Kontakt:
Phone: +49 6102-7480-
Phone (ext.): 426
E-Mail: Sibylle.Loibl@gbg.de» Kontaktdaten anzeigen

Studienlocations
(1 von 1)

German Breast Group
63263 Neu-Isenburg
(Hessen)
GermanyRekrutierend» Google-Maps
Ansprechpartner:
Sibylle Loibl, Prof. Dr.
Phone: +49 6102 7840
Phone (ext.): 426
E-Mail: Sibylle.Loibl@gbg.de» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Breast cancer is the most common cancer malignancy in women of childbearing age after the age

of 25 years. Since the incidence of breast cancer under the age of 40 is increasing, and

women tend to delay pregnancy into later reproductive years, the coincidence of pregnancy and

breast cancer is increasing. About 1 in 1,000 pregnancies is complicated by breast cancer.

Nevertheless, little is known about the right therapy for the mother and the unborn child. We

are therefore carrying out a trial, collecting prospective and retrospective data about

pregnant women, with histological confirmed breast cancer. Data on the biology of the tumour

and placenta tissues is also collected. The anonymous data is collected in a database.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Cohort 1: Women with histologically confirmed breast cancer during pregnancy

- Cohort 2: Patients ≤ 40 years with histological confirmed breast cancer who are not

pregnant (patients who have been pregnant recently can also be collected into this

cohort)

- Informed consent for data collection (for prospective participants) and biomaterial

collection. For retrospective participants an informed consent is not required as long

as the data are anonymously captured

Exclusion Criteria:

- Cohort 1: Diagnosis of breast cancer outside the period of pregnancy

- Cohort 2: Age at diagnosis of breast cancer > 40 years

Quelle: ClinicalTrials.gov